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Background: There is a great need in the treatment of schizophrenia for a drug, or drug 
  combinations, to improve clinical response with fewer serious side effects. The objective of this 
study was to explore the therapeutic effects and tolerability of the anticonvulsant gabapentin as 
an adjunctive in the treatment of patients with partially responsive schizophrenia.
Methods: Ten consenting patients with a confirmed Diagnostic and Statistical Manual of 
Mental Disorders, 4th Edition, Text Revision diagnosis of schizophrenia were identified. All 
patients failed at least one 12-week treatment trial with risperidone or olanzapine. Gabapentin 
was added to ongoing antipsychotic treatment with olanzapine or risperidone for eight weeks. 
The primary outcome measure was the Positive and Negative Syndrome Scale (PANSS). Other 
scales included the Calgary Depression Scale (CDSS) and the Abnormal Involuntary Movement 
Scale (AIMS). Repeated-measures multivariate analysis of variance was utilized to examine 
changes in outcome measures over time with adjunctive treatment with gabapentin.
Results: There was a significant drop in the PANSS and CDSS scores at endpoint (week 8). 
There were no significant differences between the two treatment groups with regard to changes 
in all outcome measures or in AIMS score. The adjunctive treatments were well tolerated and 
side effects were transient.
Conclusion: Gabapentin could be used successfully as an adjunct to novel antipsychotics in 
partially responsive schizophrenia. However, large controlled studies are needed to examine 
the effectiveness of gabapentin in psychotic disorders.
Keywords: schizophrenia, refractory, adjunctive treatment, gabapentin, risperidone, 
olanzapine
Introduction
Treatment-resistant or refractory schizophrenia is a difficult to define condition of 
largely unknown prevalence.1 The most commonly accepted definition of treatment-
resistant schizophrenia denotes patients with schizophrenia who, despite at least two 
adequate trials of classical neuroleptic drugs, have persistent moderate to severe   positive, 
disorganized, or negative symptoms, together with poor social and work   function over 
a prolonged period of time. This definition reflects the viewpoint of people with this 
illness, their family members, and mental health care providers.   Approximately 30% 
(range 10%–45%) of schizophrenic patients meet these   criteria.2 Clozapine has been 
the standard treatment in this condition and is recognized   unequivocally as being the 
most effective for refractory schizophrenia, even when stringently defined.1,3 In one 
large study (FIN-11, n = 66,881) it was found that long-term treatment with antipsy-
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and that the lowest risk was for clozapine compared with other 
antipsychotics.4,5 However, the results from an earlier large 
follow-up study (n = 1415) failed to support the hypothesis 
that clozapine treatment is associated with significantly fewer 
deaths due to suicide,6 and in a recent critical appraisal, others 
identified a number of methodologic and conceptual issues 
with these claims, which make the interpretation of these 
findings problematic.7
Despite the fact that clozapine is uniquely effective 
in refractory schizophrenia, it is associated with high 
  attrition rates, and those who discontinue treatment are 
more likely to have suffered significantly from poor out-
comes.8   Furthermore, a substantial minority fail to benefit 
from clozapine.9 Clozapine has also been associated with 
  bothersome side effects, some of which are serious, eg, 
agranulocytopenia, so needs regular full blood count monitor-
ing, which makes its administration a cumbersome process 
for both patient and clinicians.10,11
It has been demonstrated in a number of studies that gam-
ma-aminobutyric acid (GABA)-ergic medications may have a 
potential role in the treatment of schizophrenia. For example, 
laboratory evidence has generally supported the ability of 
GABA to reduce dopaminergic activity, and has suggested 
that GABA may be effective in combating   hypofrontality by 
acting on the mesoprefrontocortical tracts in patients resistant 
to treatment with antipsychotic drugs.12,13 As a result, it has 
been claimed by some investigators that it might be possible 
to decrease negative symptoms and   cognitive impairment in 
people with schizophrenia by   treatment with glutamatergic 
drugs.13
Gabapentin is a novel anticonvulsant that is structurally 
related to GABA. It was synthesized as a structural analog 
of GABA, which is a well-known inhibitory neurotransmitter 
in the brain, with the hope that it would penetrate into the 
brain and have a GABA-mimetic effect.14 The mechanism 
of action of gabapentin is not yet fully understood, and 
there is no convincing evidence to suggest that it interacts 
with GABAA or GABAB receptors. Some investigators 
have proposed that gabapentin acts as an agonist at a sub-
unit of GABAB receptors, although the evidence for this 
is conflicting.15,16 However, its role in the brain may be 
indirectly related to glutamate. Also, gabapentin has not 
been identified as a GABA reuptake inhibitor, and it is not 
converted to a GABA agonist.15,17 Gabapentin is a ligand of 
the α2 voltage-activated calcium channel subunits that are 
overexpressed in sensory neurons after nerve injury, which is 
the proposed mechanism of action of its analgesic effects.18 
Gabapentin is not metabolized in humans, does not bind 
to plasma   proteins, and is eliminated by renal excretion. 
Compared with other antiepileptic mood stabilizers, eg, 
carbamazepine and   valproate, gabapentin has milder side 
effects, is well     tolerated, is relatively safe in overdose, and 
is safe in combination with other antiepileptics.19 The most 
commonly encountered side effects include somnolence, 
dizziness, unsteadiness, nausea, and fatigue.20
From reviewing the literature, there is one case report 
of a patient with resistant schizophrenia who was treated 
with gabapentin and antipsychotic therapy in an open-label 
case study. In this case report, the authors reported that their 
patient’s aggressive behavior stabilized after the administra-
tion of gabapentin. However, the patient’s aggression resumed 
after cessation of gabapentin and restabilized following the 
drug’s reintroduction.21 This was supported by others who 
found that adjunctive gabapentin was associated with a reduc-
tion in agitation in chronically hospitalized schizophrenic 
patients.22 There has also been an open-label trial (n = 25) 
in which gabapentin was effective in the treatment of inpa-
tients with bipolar disorder and schizoaffective disorders. 
The authors reported that 76% had a positive response, as 
measured by changes in Clinical Global Impression and 
Brief Psychiatric Rating Scale scores, and that the mean dose 
was 1440 mg/day.23,24 Gabapentin was found to be effective 
in antipsychotic-induced akathisia that is unresponsive to 
conventional therapy,25 in the treatment of tardive dyskine-
sia, in antipsychotic-induced blepharospasm, in involuntary 
oromandibular movements,26 and in prophylaxis of clozapine-
induced seizures.27
The author is not aware of any published controlled or 
open studies to date that have examined the efficacy and toler-
ability of gabapentin as an adjunctive to novel antipsychotics 
in the treatment of partially responsive schizophrenia. The 
objective of this pilot open-label study was to examine 
the therapeutic outcomes of adding gabapentin to existing 
prescribed antipsychotics in patients with the diagnosis of 
chronic partially responsive schizophrenia.
Methods
study design
This was an eight-week open study of add-on use of gabapen-
tin in subjects with chronic schizophrenia, who showed only 
a partial response to 12 weeks of treatment with olanzapine 
or risperidone. All patients provided informed consent. This 
study was approved by the University of Calgary Conjoint 
Scientific and Ethics Board.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Participants
Patients recruited for this study were consenting males and 
females, aged 18–65 years, from an inpatient psychiatry 
unit of a teaching hospital. All patients had a Diagnostic 
and Statistical Manual of Mental Disorders, 4th Edi-
tion, Text   Revision diagnosis of paranoid schizophrenia, 
confirmed by the   Mini-International Neuropsychiatric 
Interview.28 All patients had shown a partial response to 
risperidone or olanzapine treatment for 12 weeks prior 
to adding gabapentin. Partial response was evidenced 
by ,20% reduction in the total Positive and Negative 
Syndrome Scale (PANSS) score,29 and all patients had a 
total PANSS score $80 at baseline prior to adding gabap-
entin. All patients were treated as inpatients and remained 
adherent to the gabapentin adjunctive treatment for at 
least eight weeks. Patients with suicidal thoughts, mental 
retardation, head injury or organic brain disease, renal or 
hepatic impairment, and/or excessive use of alcohol or 
illicit drugs during the six weeks prior to consideration 
for the trial were excluded.
Drug administration
Gabapentin was added to the existing risperidone or 
olanzapine regimen and was titrated from 100 mg three 
times a day with daily increments of 300 mg a day as 
tolerated to a maximum of 1800 mg a day. No patient 
received other concomitant antipsychotics during the 
eight weeks of adjunctive treatment with gabapentin. 
Zopiclone 7.5 mg was utilized occasionally for sleep 
difficulties, and lorazepam 1–2 mg was utilized for 
severe agitation.
Outcome measures
Subjects underwent standardized ratings at baseline (before 
the addition of gabapentin) and at weeks 4 and 8 after 
addition of gabapentin. Outcome measures included changes 
in PANSS score29 (the primary efficacy measure), Calgary 
Depression Scale (CDSS),30 the Abnormal Involuntary 
Movement Scale (AIMS),31 and reported side effects.
Data analysis
Descriptive statistics were used to summarize demographic 
variables, duration of the illness, number of previous 
admissions for acute psychotic episodes, and types of 
  previously failed novel antipsychotics. To examine changes in 
PANSS positive scores and CDSS scores over time in both the 
olanzapine and risperidone patients, we employed a repeated-
measures multivariate analysis of variance (MANOVA). The 
dependent variables were the total PANSS scores and the 
CDSS scores. The two independent variables were time (three 
levels, ie, at baseline and at weeks 4 and 8) and treatment 
group (risperidone and olanzapine). The paired t-test was 
used to examine changes in AIMS scores, by pairing scores 
at baseline before adding gabapentin and those at week 8, 
and one-way analysis of variance was used to examine dif-
ferences in extrapyramidal symptom (EPS) scores between 
the risperidone and olanzapine treatment groups. The paired 
t-test was used to examine changes in AIMS at baseline and 
at week 8 of adjunctive treatment in each group.
Results
Table 1 summarizes the demographic variables, history of 
past hospitalizations for acute psychotic episodes, and details 
Table 1 Demographics of subjects
Risperidone (n = 5) Olanzapine (n = 5)
Mean (SD) Minimum–Maximum Mean (SD) Minimum–Maximum
Age (years) 37.2 (8.17) 28–49 40 (9.3) 27–52
sex (M/F) 4/5 80% 5/0 100% 
Duration of illness (years) 10 (6.14) 5–20 16.6 (8.8) 8–30
Number of acute hospital treatments 2.2 (0.84) 1–3 3.2 (1.4) 1–8
Novel dose at baseline (mg)* 4.6 (0.9) and dose range 4–6 20 (0) and dose range 20–20
Gabapentin dose (mg) 1200 (367) 900–1800 1080 (402) 900–1800
History of partial response to other 
antipsychotic trials
Patients (n) Patients (n)
Previous novel antipsychotics alone 1 1
Traditional oral antipsychotics 3 2
Depot iM injections (eg, haldol 
decanoate or fluphenazine decanoate)
2 2
Note: *Prior to adding gabapentin adjunctive treatment. 
Abbreviations: iM, intramuscular; sD, standard deviation.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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of partial response to previous treatments with antipsychotics. 
Ten patients (100%) completed the eight-week trial of adjunc-
tive treatment with gabapentin, and all patients were rated as 
moderately to severely ill before adjunctive treatment with 
gabapentin was initiated. Table 2 summarizes the results from 
the repeated-measures one-way analysis of variance for the 
total PANSS and CDSS outcome measures over time in all 
patients and in each novel treatment group. There were no 
significant differences between the risperidone and olanzap-
ine treatment groups in any of the outcome measures. On the 
primary efficacy measure, there was a significant decrease 
in total PANSS scores for both olanzapine and risperidone 
patients (P , 0.001). At endpoint (week 8 of adjunctive 
treatment) there were four patients (80%) in the risperidone 
group and two patients (40%) in the olanzapine group who 
achieved a response with .50% reduction in total PANSS 
score. Table 3 summarizes the calculated percentage of reduc-
tion in the PANSS scores in the two treatment groups.
The percentage of PANSS reduction was calculated by the 
following formula to take into account the value of 30 mean-
ing “no symptoms” on the 1–7 scoring system of PANSS:
(PANSS baseline – PANSS at 8 weeks) × 100
PANSS at 8 weeks – 30
A response rate based on percentage PANSS reduction, 
ie, a cutoff of at least 50% reduction, has been recommended 
recently to be used at least for acutely ill patients.32
Tolerance to adjunctive treatment
The adjunctive treatments were well tolerated in both 
risperidone and olanzapine patients. There was significant 
changes (df 9; P , 0.4) at week 8 in AIMS scores (Table 2). 
The most commonly encountered extrapyramidal symptoms 
included parkinsonian tremors, hypokinesia, and rigidity. 
However, these symptoms appeared to improve in severity 
over time with adjunctive gabapentin treatment. At week 8, 
there were no significant changes in AIMS score in either 
of the groups, nor any significant difference between the 
two treatment groups. All other side effects were mild and 
transient. These included sedation, drowsiness, dizziness, 
and headaches. At baseline (prior to adding gabapentin), two 
patients in each of the treatment groups reported parkinsonian 
symptoms, including tremors and rigidity, which seemed to 
improve in severity by week 8 of adjunctive treatment. All 
patients elected to continue on adjunctive treatment at the 
end of the trial. Table 4 outlines the reported side effects and 
AIMS score profile.
Discussion
In the present open pilot study, there was significant improve-
ment in positive, general psychopathology and depressive 
symptoms in schizophrenic patients treated with gabapentin 
adjunctive to the atypical antipsychotics risperidone and 
olanzapine.
Despite being configurationally similar to GABA (known 
to be an inhibitory transmitter in the brain), gabapentin does 
not bind to GABA receptors. In contrast with earlier stud-
ies that failed to demonstrate that gabapentin can affect the 
neuronal content of GABA, more recent evidence suggests 
that gabapentin may increase GABA synthesis and decrease 
glutamatergic excitability by depressing astrocytic activity 
Table 2 changes in PANssa and cDssa over eight weeks employing repeated-measures multivariate analysis of variance
Measure  Groups Time Mean (SD) 95% CI
Lower limit Upper limit
PANss All patients Baseline 104 (19.2) 89.8 118.1
4 weeks 90 (13.4) 80.5 99.7
8 weeks 78 (10.6) 70.6 85.8
PANss risperidone Baseline 108 (16.9) 87.0 129
    4 weeks 90 (12.3) 75.8 105.0
    8 weeks 78 (6.3) 66.4 89.6
  Olanzapine Baseline 101 (22.5) 80.1 121.1
    4 weeks 90 (15.8) 75.2 104.4
    8 weeks 78 (14.6) 66.8 90.0
cDss risperidone Baseline 13 (2.0) 8.4 18.0
    4 weeks 7 (2.7) 4.7 10.1
    8 weeks 3 (2.5) 0.4 5.6
  Olanzapine Baseline 16 (6.3) 11.4 21.0
    4 weeks 10 (2.4) 7.3 12.7
    8 weeks 5 (2.5) 1.1 7.21
Note: aPANss P , 0.001; cDss P , 0.001. 
Abbreviations: CI, confidence interval; SD, standard deviation; PANSS, positive and negative syndrome scale; CDSS, calgary depression scale.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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and suppressing glial calcium signaling and glutamate 
release.20,33 Although the present findings need further criti-
cal examination, they suggest that gabapentin functions as 
a GABA-ergic drug. Also, these findings would support the 
GABA hypothesis of schizophrenia, which suggests that there 
is insufficient GABA inhibition of dopaminergic neurotrans-
mission in patients with schizophrenia.34–36
Antiepileptic drugs are commonly prescribed for major 
nonepileptic psychiatric disorders, including schizophre-
nia and bipolar disorders.37–40 There is some evidence that 
antiepileptic drugs, including carbamazepine, valproate, 
and lamotrigine, may change symptoms of schizophrenia 
by their action on GABA-ergic neurotransmission, or via 
antiglutamatergic mechanisms, by modifying the excitability 
of neurons through effects on voltage-gated sodium and 
calcium channels, or by promoting inhibition mediated 
by GABA receptors. Also, there is emerging evidence to 
suggest that antiepileptic drugs have effects on signaling 
pathways that regulate neuronal plasticity and survival.15,39,41 
For example, the traditional antiepileptic carbamazepine was 
identified as a useful adjunct to antipsychotics in the treat-
ment of resistant schizophrenia, with particular effects on 
reduction of violent and aggressive behavior, in improving 
the associated affective disturbances.42 The new antiepilep-
tics (eg, gabapentin, oxcarbazepine, topiramate, vigabatrin) 
have promise as potential adjuncts to antipsychotics for 
treating resistant symptoms of schizophrenia.41 For example, 
in a recent meta-analysis, it was concluded that lamotrigine 
augmentation may be an effective treatment for patients 
with clozapine-resistant schizophrenia, and that a substan-
tial proportion of the most severely ill patients appeared 
to obtain clinically meaningful benefit from this combina-
tion treatment.43,44 However, results from two multicenter, 
randomized, double-blind studies did not support the use 
of lamotrigine as an adjunct to atypical antipsychotics in 
patients with refractory psychosis.45
Knowledge of the sites and mode of action of anti-
epileptic drugs, such as gabapentin in the synapse, is 
important in order for us to improve our understanding of 
their broad spectrum of clinical efficacy and to develop 
effective drugs for the treatment of both epilepsy and other 
neurologic and psychiatric disorders in the future. Therefore, 
further studies are needed at the molecular level to examine 
the mode of action of gabapentin in different brain tissues. 
In the years to come, continued investigations of the GABA 
system in the rodent, primate, and human brain, and the 
characterization of changes in specific phenotypic subclasses 
of interneurons in schizophrenia and bipolar disorder, will 
undoubtedly provide important new insights into how the 
integration of this transmitter system may be altered in 
neuropsychiatric disease.46
Conclusion
This study is probably the first open-label pilot research 
examining clinical outcomes of adjunctive treatment with 
gabapentin in partially responsive schizophrenia. Although 
clozapine is currently the recommended drug for resistant 
schizophrenia when other antipsychotics fail, it is associated 
with a number of limitations, some of which are serious. This 
makes the administration of clozapine a cumbersome process 
for both patients and clinicians. At this point in time, there is 
a great need for a drug or drug combinations to have a more 
effective clinical response with fewer serious side effects.
Gabapentin may have properties that enhance anti 
psychotic effects when added to antipsychotics in patients 
Table 3 The percentage of PANss reduction in the two treatment groups
Response rate/ 
treatment groups
Patients  
(n)
0%–25%  
PANSS 
reduction 
n (%)
25%–49%  
PANSS 
reduction 
n (%)
50%–74%  
PANSS 
reduction 
n (%)
75%–100%  
PANSS 
reduction 
n (%)
Response rate  
with .50% 
PANSS reduction 
n (%)
risperidone group 5 1 (20) 0 3 (60) 1 (20) 4 (80)
Olanzapine group 5 0 3 (60) 2 (40) 0 2 (40)
Abbreviation: PANss, positive and negative syndrome scale.
Table 4 Reported side effects and AIMS score profile
Reported side effects Risperidone  
(n = 5)
Olanzapine  
(n = 5)
n (%) n (%)
Drowsiness 2 (40)  3 (60)
Dizziness 2 (40) 2 (40)
headaches 1 (20) 0
EPS profile at baseline
Parkinsonian bradykinesia 1 (20) 1 (20)
Tremors 2 (40) 1 (20)
rigidity 1 (20) 1 (20)
AiMs scores (n = 5; df 4) M (sD), t , P M (sD), t , P
Baseline 2.4 (2.5) 1.6 (2.3)
Week 8 2 (2.0), 1.6  0.2 1.2 (1.7), 1.6  0.2
Abbreviations: AiMs, abnormal involuntary movement scale; ePs, extrapyramidal 
symptom; sD, standard deviation.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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suffering from schizophrenia. However, the significance of the 
results from the current study needs to be interpreted cautiously 
because of its limitations, which include a small sample, an 
open study design, the absence of a clozapine treatment arm, 
and the lack of a systematic safety evaluation. Further con-
trolled, double-blind studies are needed to examine the efficacy 
of gabapentin in the treatment of schizophrenia.
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